DelveInsight’s ‘Epidemic keratoconjunctivitis (EKC) Market Insights, Epidemiology, and Market Forecast–2032’ report delivers an in-depth understanding of the EKC, historical and forecasted epidemiology as well as the EKC market trends in the United States, EU-5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.
The EKC market report provides current treatment practices, emerging drugs, and market share of individual therapies, current and forecasted 7MM EKC market size from 2019 to 2032. The Report also covers current EKC treatment practice, SWOT analysis, reimbursement, and market access, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.
Some of the key facts of Epidemic Keratoconjunctivitis Market Report:
- DelveInsight’s analysis estimates that in the United States, the total incident cases of Viral conjunctivitis were ~2,756,000 and the Adenovirus D-specific incident cases were ~1,290,000 in the year 2021.
- Germany had the highest total incident cases of Viral conjunctivitis and Adenovirus D-specific incident cases among the EU-5 countries. In 2021, Germany accounted for ~950,000 total incident cases of Viral conjunctivitis and ~573,000 Adenovirus D-specific cases
- As per DelveInsight’s analysis, in Japan, ~501,000 total diagnosed incident cases of Epidemic keratoconjunctivitis were observed in 2021.
- The total number of diagnosed incident cases of EKC in the United States were found to be ~58,000 in 2021. Among the EU-5 countries, Germany had ~10,000 diagnosed incident cases and Spain had the lowest diagnosed incident cases of EKC, i.e. ~6000 cases in 2021.
Key Benefits of the Report:
- The report covers the descriptive overview of EKC, explaining its causes, symptoms, pathophysiology, genetic basis, and currently available therapies.
- Comprehensive insight has been provided into the EKC epidemiology and treatment.
- A detailed review of the EKC market; historical and forecasted is included in the report, covering the 7MM drug outreach.
- The report provides an edge while developing business strategies, by understanding trends shaping and driving the 7MM EKC market.
Got queries? Click here to know more about the Epidemic keratoconjunctivitis Market Landscape
Epidemic Keratoconjunctivitis Overview
Conjunctivitis (pink eye) is an inflammation or infection of the transparent membrane (conjunctiva) that lines the eyelid and covers the white part of the eyeball. When small blood vessels in the conjunctiva become inflamed, they become more visible, and this is what causes the whites of the eyes to appear reddish or pink. Pink eye is commonly caused by a bacterial or viral infection, an allergic reaction, or – in babies – an incompletely opened tear duct. Viral infections cause nearly 80% of all conjunctivitis cases. Many different viruses, such as adenovirus, which typically leads to the common cold, can be the source of infection. Viral conjunctivitis spreads easily via a touch from person to person, making outbreaks common.
Epidemic Keratoconjunctivitis Epidemiology Insight
- Epidemic keratoconjunctivitis (EKC) is a highly contagious viral conjunctivitis. It is caused by a group of viruses known as adenoviruses that, in addition to ocular surface infections, are responsible for causing infectious diseases of the gastrointestinal tract and respiratory system illnesses such as the common cold virus. EKC has a long incubation period and is highly contagious, leading to large outbreaks worldwide.
- The total incident cases of EKC in the 7MM in 2021 were ~1,821,000. These cases are expected to increase during the forecast period [2022–2032].
- According to DelveInsight’s analysis, in the 7MM, the Japan reported the highest incident cases of EKC, i.e., ~993,000, in the year 2021.
- Among the EU-5 countries, the highest number of cases (incident) of EKC were in Germany, i.e. ~86,000 cases in the year 2021.
- The total incident cases of EKC in the United States in 2021 were ~503,000. These cases are expected to increase during the forecast period [2022–2032].
- Among the EU-5 countries, the lowest number of cases of EKC were observed in Spain, i.e. ~48,000 cases in the year 2021.
Epidemic Keratoconjunctivitis Epidemiological Segmentation
- Epidemic keratoconjunctivitis Total Incident Cases
- Epidemic keratoconjunctivitis total specific incident cases
- Epidemic keratoconjunctivitis total diagnosed incident cases
Epidemic Keratoconjunctivitis Market Outlook
Epidemic keratoconjunctivitis (EKC) is a self-limiting, infectious, viral, and highly contagious ocular condition that starts unilaterally and later develops into a bilateral condition. Adenovirus is the causative agent for this infection. During EKC infection, a patient has symptoms of both keratitis and conjunctivitis simultaneously. Some typical signs of EKC include conjunctival hyperemia/erythema (redness) of bulbar conjunctiva and/or palpebral conjunctiva; epithelial keratitis; chemosis (conjunctival edema); photophobia; foreign body sensation, etc. Other than these ocular symptoms, some of the systemic symptoms associated with EKC are lymphadenopathy (swollen lymph nodes, specifically the preauricular lymph nodes); fever; headache; and fatigue.
Learn more by requesting for sample @ Epidemic Keratoconjunctivitis Market Landscape
Table of Contents
- Key Insights
- Report Introduction
- Executive Summary of Epidemic keratoconjunctivitis
- Disease Background and Overview
- Epidemiology and patient population
- The United States
- EU 5
- Epidemic keratoconjunctivitis Emerging Therapies
- Epidemic keratoconjunctivitisCancer Market Outlook
- Market Access and Reimbursement of Therapies
- Appendix
- Epidemic keratoconjunctivitis Report Methodology
- DelveInsight Capabilities
- Disclaimer
- About DelveInsight
Click here to read more about Epidemic keratoconjunctivitis market Landscape
Media Contact
Company Name: DelveInsight Business Research
Contact Person: Adya Kaul
Email: Send Email
Phone: +91 9568243403
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/